Pfizer's Viagra comes with more side effects than ED rivals; Aurobindo affiliate hurls fraud allegations;

@FiercePharma: ICYMI from FiercePharmaManufacturing: UAE drug distributor building a $20M plant in Dubai. Report | Follow @FiercePharma

@EricPFierce: Hospira has now received FDA warning letters for plants on 4 of 7 continents. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire could use boost from adult ADHD med to hit $10B goal. Report | Follow @CarlyHFierce

> Pfizer's ($PFE) Viagra may be the most effective treatment for erectile dysfunction, but it also has a higher rate of side effects than other options, according to a new analysis. Report

> Pfizer Canada is giving Shoppers Drug Mart credit for alerting the public that expired pills had recently been dispensed. More

> An affiliate of India's Aurobindo Pharma has alleged that former owner of a natural products company it bought out of a U.S. bankruptcy proceeding committed fraud. Report (sub. req.)

> Spain's Laboratorio Reig Jofre has purchased the licenses of four dermatological products in the U.K. from Dema UK. Report

Medical Device News

@FierceMedDev: FDA approves breath test for stomach disorder, highlights its ease of use over standard of care. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Alere earns FDA clearance for rapid diagnostic of Strep A. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: AdverseEvents: Analysis of side-effect reports turns up troubling safety signals for Novartis, Eisai drugs. Article | Follow @EmilyWFierce

> FDA recalls fall more than 50% in Q1 2015 after reaching record high in 2014. More

> Study: False alarms of breast cancer costing U.S. $4B a year. Story

> Medtronic debuts European study of its atrial fibrillation device. Article

Biotech News

@FierceBiotech: ICYMI: Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. Story | Follow @FierceBiotech

@JohnCFierce: Alzheimer's startup Alzheon bags $10M and beats a path to Phase III. Article | Follow @JohnCFierce

@DamianFierce: ICYMI: Life sciences entrepreneurs, here is my gift to you: The Biotech Name Generator | Follow @DamianFierce

> Rhythm rolls into Phase IIb with an Actavis buyout in the balance. Report

> Merck (sort of) wins back 'breakthrough' boasting rights on hep C. Article

> Woodford to U.S.: You're in a bubble. We're not. More

Pharma Marketing News

> Next DTC push for Linzess: Spotlight patients, with big salesforce backup. More

> Pfizer, Merck KGaA suit up for Xalkori marketing wave. Report

> Does pricier mean better to ad consumers? FDA means to find out. Article

> Patient portals open door to lasting relationships with patients, 'Digital Doctor' says. Story

> Pfizer wants Canadians to think EpiPen. What else but a hockey partnership? More

Biotech Research News

> Zurich investigators ID pathway for B cell lymphoma. Item

> Berkeley, Harvard groups highlight new targets for cachexia. Report

> Regulus surges after AstraZeneca snags rights to NASH drug. More

> Whitehead team adapts CRISPR-Cas9 tech to target killer fungal infections. Article

> Daiichi Sankyo partners with Sanford-Burnham on a cardio molecule. Story

Diagnostics News

> Researchers develop paper microchip and smartphone diagnostic for HIV. Item

> OpGen eyes $35M IPO for drug-resistant bacteria tests. Story

> Roche and Foundation Medicine seal $1.2B deal with plans for cancer R&D. More

> Alere earns FDA clearance for rapid diagnostic of Strep A. News

> Natera ropes in $55M with eye on cancer Dx. Article

And Finally... Type 2 diabetes patients may have less depression and fewer hunger pains if they eat a big breakfast and lunch rather than 6 smaller meals throughout the day, a new study suggests. More

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.